TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10524821

Group type: EXPERIMENTAL
Intervention: PCL reconstruction with BPTB autograft
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MRI evaluation of tunnel placement
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Clinical evaluation using KT-2000 arthrometer
Number of subjects: 70
Study: 7563259

Group type: EXPERIMENTAL
Intervention: Deltamethrin impregnated bednets
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control (no nets)
Number of subjects: 480
Study: 2261735

Group type: EXPERIMENTAL
Intervention: OM-8980
Number of subjects: 145
Study: 371903

Group type: EXPERIMENTAL
Intervention: Calcium carbimide (CC) 0.7 mg/kg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Ethanol 0.125 gm/kg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Ethanol 0.25 gm/kg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Ethanol 0.5 gm/kg
Number of subjects: 5
Study: 31913227

Group type: EXPERIMENTAL
Intervention: Physiologic VMS
Number of subjects: 14
Study: 31187863

Group type: EXPERIMENTAL
Intervention: DHA + AA (200 mg each)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 377
Study: 27787893

Group type: EXPERIMENTAL
Intervention: High-intensity intervention (video plus home-based educational session)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Low-intensity intervention (video delivered to participants' homes)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 443
Study: 25951761

Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF)
Number of subjects: 3691

Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF) requiring intravenous inotropes or mechanical therapy
Number of subjects: 3691

Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF) treated with intravenous loop diuretic alone
Number of subjects: 3691
Study: 23942596

Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 169

Group type: COMPARATOR
Intervention: Palliative care
Number of subjects: 169
Study: 22152246

Group type: EXPERIMENTAL
Intervention: Liposomal albendazole (L-ABZ)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Tablet albendazole (T-ABZ)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: L-ABZ and T-ABZ
Number of subjects: 218
Study: 18847329

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg orally once a day for 3 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17118687

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment (200 microg/day for the first month, then 400 microg/day for men and 600 microg/day for women thereafter)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14552082

Group type: EXPERIMENTAL
Intervention: Tri-sodium citrate as anticoagulant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lowering dialysis fluid bicarbonate concentration from 37 mmol/l to 25 mmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusting dialysis fluid sodium concentration from 140 mmol/l to 132 mmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Replacing glass bottles with polyvinylchloride bags
Number of subjects: 0
Study: 10752824

Group type: EXPERIMENTAL
Intervention: Olprinone (OLP) 0.3 microg/kg/min for 2 hrs
Number of subjects: 29

Group type: COMPARATOR
Intervention: Milrinone (MIL) 0.5 microg/kg/min for 2 hrs
Number of subjects: 29

Group type: COMPARATOR
Intervention: Amrinone (AMR) 10 microg/kg/min for 2 hrs
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Olprinone (OLP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Milrinone (MIL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Amrinone (AMR)
Number of subjects: 29
Study: 9557113

Group type: EXPERIMENTAL
Intervention: Postoperative patients after extensive resections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients after pancreatoduodenectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patients awaiting sinister operations (control group)
Number of subjects: 30
Study: 1403068

Group type: EXPERIMENTAL
Intervention: Aztreonam (Az)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Colistin plus Neomycin (CN)
Number of subjects: 34
Study: 4073858

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (80 mg/kg once daily after an initial dose of 100 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ampicillin plus chloramphenicol (conventional dosages)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ampicillin plus chloramphenicol
Number of subjects: 36
Study: 31835959

Group type: EXPERIMENTAL
Intervention: QR code-based information (graphic and text)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Current bottle label information
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 55

Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 55
Study: 31033362

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor (ACEI)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Estrogen-progestin therapy (EPT)
Number of subjects: 140
Study: 30942964

Group type: EXPERIMENTAL
Intervention: Sodium tripolyphosphate 2% tablets
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sodium tripolyphosphate 0.65% tablets
Number of subjects: 66

Group type: COMPARATOR
Intervention: No-tablet control
Number of subjects: 66
Study: 26988368

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) with ropivacaine plus plain lubricant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dorsal penile nerve block (DPNB) with saline (tetracaine gel group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) with ropivacaine plus tetracaine gel (combination group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB)
Number of subjects: 0
Study: 24608924

Group type: EXPERIMENTAL
Intervention: Interferon-2α therapy
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Interferon-2α combined with 5-fluorouracil
Number of subjects: 17
Study: 22964609

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 48
Study: 19647964

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infiltration of local anaesthetic and corticoid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Palpation-guided infiltration of local anaesthetic and corticoid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infiltration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Palpation-guided infiltration
Number of subjects: 20
Study: 18665163

Group type: EXPERIMENTAL
Intervention: Gemcitabine (G) added to paclitaxel (T) following epirubicin (E) and cyclophosphamide (C)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Paclitaxel (T) following epirubicin (E) and cyclophosphamide (C) without gemcitabine
Number of subjects: 135
Study: 15942766

Group type: EXPERIMENTAL
Intervention: 40 min run at 55% of VO2max
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 80 min run at 55% of VO2max
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 120 min run at 55% of VO2max
Number of subjects: 8

Group type: COMPARATOR
Intervention: Resting session
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 80 min run
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 120 min run
Number of subjects: 8
Study: 12626679

Group type: EXPERIMENTAL
Intervention: Loading (16%, 33%, 50% of body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unloading (10%, 20%, 30% of body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-loaded control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loading
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unloading
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loading conditions
Number of subjects: 0
Study: 10584133

Group type: EXPERIMENTAL
Intervention: 500 mg/m2 amifostine intravenously prior to high-dose radioiodine treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physiological saline solution (control)
Number of subjects: 50
Study: 8561761

Group type: EXPERIMENTAL
Intervention: Group treatment for hypochondriasis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 14
Study: 1667511

Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus (AM) intravenous 24 g/d infused into 5% glucose 250 ml
Number of subjects: 67

Group type: COMPARATOR
Intervention: 5% glucose 250 ml
Number of subjects: 67
Study: 6406649

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard Enteral Nutrition (SEN)
Number of subjects: 38
Study: 31373982

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 17
Study: 29654840

Group type: EXPERIMENTAL
Intervention: Acupuncture for 20 minutes/day, for 15 days/month, for 90 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 60
Study: 26858433

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) administered intranasally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered intranasally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP)
Number of subjects: 0
Study: 23909858

Group type: EXPERIMENTAL
Intervention: Electronic intervention + treatment as usual (TAU)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 92
Study: 22379116

Group type: EXPERIMENTAL
Intervention: Unacylated ghrelin (UAG) infusion (1.0 μg/kg per h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 20639355

Group type: EXPERIMENTAL
Intervention: Metformin (2×500 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 18520682

Group type: EXPERIMENTAL
Intervention: Single-dose TDF (300 mg)/FTC (200 mg)
Number of subjects: 397

Group type: COMPARATOR
Intervention: No intervention in labor (Control)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Single-dose TDF/FTC
Number of subjects: 397

Group type: COMPARATOR
Intervention: No antenatal ZDV (Control)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Other antiretroviral drugs
Number of subjects: 397
Study: 15948007

Group type: EXPERIMENTAL
Intervention: Interictal brain perfusion 99mTc‐ethylcysteinate dimer (ECD) SPECT in PKC patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 16
Study: 12390715

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine (Group R, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.125% bupivacaine (Group B, n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Group R and Group B)
Number of subjects: 20
Study: 9932994

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily (n = 466)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily (n = 371)
Number of subjects: 837
Study: 8850571

Group type: EXPERIMENTAL
Intervention: High contextual interference group (practised the skill on alternate sides)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low contextual interference group (followed U'ren's recommendations)
Number of subjects: 16
Study: 1967597

Group type: EXPERIMENTAL
Intervention: Prazosin (0.5 mg, incremented to a final dose of 2.5 +/- 1.7 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (3.1 +/- 2.0 mg)
Number of subjects: 38
Study: 7438696

Group type: EXPERIMENTAL
Intervention: Loperamide (60 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Codeine (120 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31591826

Group type: EXPERIMENTAL
Intervention: Ivabradine on top of guideline-directed medical therapy (GDMT)
Number of subjects: 3357
Study: 28631527

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone 4mg/1mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Methadone 30mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Methadone/lofexidine
Number of subjects: 80
Study: 25864745

Group type: EXPERIMENTAL
Intervention: Food Supplement (FS) alone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Thyroid hormones alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: FS plus thyroid hormones
Number of subjects: 45
Study: 23758458

Group type: EXPERIMENTAL
Intervention: Pastinject
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bi‐directional spiral
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pressure syringe
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pastinject and Pressure syringe
Number of subjects: 29
Study: 21129755

Group type: EXPERIMENTAL
Intervention: Early and high AA (2 g/kg/d, increased by 1 g/kg daily to 4 g/kg/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard AA (0.5 g/kg/d, increased by 0.5 g/kg daily to 3 g/kg/d)
Number of subjects: 62
Study: 19684408

Group type: EXPERIMENTAL
Intervention: Spousal donor grafts
Number of subjects: 445

Group type: COMPARATOR
Intervention: Other LUD grafts
Number of subjects: 445
Study: 17895439

Group type: EXPERIMENTAL
Intervention: Community occupational therapy (10 sessions over 5 weeks)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 135
Study: 15298427

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (30 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 60
Study: 11830754

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study: 11084131

Group type: EXPERIMENTAL
Intervention: MIST VR (virtual reality training)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal laparoscopic imaging
Number of subjects: 24

Group type: COMPARATOR
Intervention: Randomly alternating imaging (y-axis inverted and normal laparoscopic)
Number of subjects: 24
Study: 8874912

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 0.2 mg.kg‐1 i.m.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.06 mg.kg‐1 i.v.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 0.1 mg.kg‐1 i.v.
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo (isotonic saline) 0.02 ml.kg‐1 i.v.
Number of subjects: 148
Study: 1574960

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) 300 U/kg subcutaneously 3 times weekly for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional support alone (control)
Number of subjects: 30
Study: 3881068

Group type: EXPERIMENTAL
Intervention: Serial impedance plethysmography alone
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Combined impedance plethysmography and leg scanning
Number of subjects: 634
Study: 29209951

Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS) assessment
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Baseline late heart-to-mediastinum ratio (HMR)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: GLS assessment at baseline
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: GLS cut-off of -9%
Number of subjects: 81
Study: 29801081

Group type: EXPERIMENTAL
Intervention: Early referral to the vision center for refraction and free eyeglasses if needed (n=433)
Number of subjects: 2613

Group type: COMPARATOR
Intervention: Late referral to the vision center for refraction and free eyeglasses if needed (n=516)
Number of subjects: 2613
Study: 26739975

Group type: EXPERIMENTAL
Intervention: 1 μ/kg dexmedetomidine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 250 μ/kg intravenous ketamine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 75
Study: 24966055

Group type: EXPERIMENTAL
Intervention: Managed care
Number of subjects: 783

Group type: COMPARATOR
Intervention: Protocolized care
Number of subjects: 783

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 783
Study: 22507606

Group type: EXPERIMENTAL
Intervention: Chicken-based formula
Number of subjects: 58

Group type: COMPARATOR
Intervention: Extensively hydrolyzed protein formula
Number of subjects: 58
Study: 20805017

Group type: EXPERIMENTAL
Intervention: Allowed to drink at home with friends
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Allowed to drink at home with family meals
Number of subjects: 449

Group type: COMPARATOR
Intervention: Not permitted to drink at all
Number of subjects: 449
Study: 17909934

Group type: EXPERIMENTAL
Intervention: Posteriorly stabilized total knee arthroplasty (PS TKA)
Number of subjects: 16
Study: 16269092

Group type: EXPERIMENTAL
Intervention: Psilocybin (215 microg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketanserin (50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Psilocybin and Ketanserin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 8
Study: 12175997

Group type: EXPERIMENTAL
Intervention: Saturday night social activities (discotheque)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 59

Group type: COMPARATOR
Intervention: Daytime assessment (9:00‐11:00 a.m.)
Number of subjects: 59
Study: 10661604

Group type: EXPERIMENTAL
Intervention: Harassment condition (telling stories with harassment)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nonharassment condition (telling stories without harassment)
Number of subjects: 102
Study: 8547382

Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation Unit (GEU) care
Number of subjects: 249

Group type: COMPARATOR
Intervention: Standard care in the National Health Care System (control group)
Number of subjects: 249
Study: 2312764

Group type: EXPERIMENTAL
Intervention: 4 mg intravenous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg oral solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.7 mg intravenous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12 mg intravenous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration
Number of subjects: 0
Study: 31359099

Group type: EXPERIMENTAL
Intervention: Medication review using STOPP/START criteria
Number of subjects: 180

Group type: COMPARATOR
Intervention: Similar review without a recommendation
Number of subjects: 180
Study: 28797048

Group type: EXPERIMENTAL
Intervention: Proximal condition (food placed near students)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Distal condition (food placed 6 meters away from students)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Proximal condition
Number of subjects: 41

Group type: COMPARATOR
Intervention: Distal condition
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 41
Study: 25577461

Group type: EXPERIMENTAL
Intervention: Detection and quantitation of the α‐1 haptoglobin fragment in the culture medium.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Microscopic inspection of embryos during IVF process.
Number of subjects: 53
Study: 23444965

Group type: EXPERIMENTAL
Intervention: Emulin/no medication
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Emulin/metformin
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo/no medication
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo/metformin
Number of subjects: 40
Study: 21211642

Group type: EXPERIMENTAL
Intervention: Timothy grass AIT treatment (2,800 bioequivalent allergen units, approximately 15 μg of Phl p 5)
Number of subjects: 345
Study: 19758607

Group type: COMPARATOR
Intervention: High doses of progestin and endometrial protective doses of estradiol, administered immediately after delivery and continuously during the first three months post-partum.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 126
Study: 18032935

Group type: EXPERIMENTAL
Intervention: HIV-positive individuals
Number of subjects: 240

Group type: COMPARATOR
Intervention: HIV-negative individuals
Number of subjects: 240
Study: 15508056

Group type: EXPERIMENTAL
Intervention: Levovist (1 g i.v. injection)
Number of subjects: 12
Study: 11336120

Group type: EXPERIMENTAL
Intervention: Orthodontist-delivered anti-tobacco counseling
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Social learning variables
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Financial incentives, tracking prescriptions, prompting positive feedback from patients, adopting anti-tobacco counseling models
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Training orthodontists
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Preventing tobacco use
Number of subjects: 154
Study: 9134645

Group type: EXPERIMENTAL
Intervention: Thrombin generation markers (TAT and F1 + 2)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: F1 + 2
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Total plasma cholesterol
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Thrombin generation markers
Number of subjects: 195
Study: 7928859

Group type: EXPERIMENTAL
Intervention: 10% carbohydrate (CHO) drink (CI) at 500 ml/h
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PI) at 500 ml/h
Number of subjects: 14
Study: 2905341

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mepindolol 10 mg/day
Number of subjects: 69

Group type: COMPARATOR
Intervention: All beta-blockers
Number of subjects: 69

Group type: COMPARATOR
Intervention: None of the beta-blockers
Number of subjects: 69
Study: 30586720

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 110

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 110
Study: 28234152

Group type: EXPERIMENTAL
Intervention: Nasal rinsing with hypertonic solution buffered to pH 6.1, three times daily before and during peak pollen season
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no nasal treatment)
Number of subjects: 40